Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
Clinical development and economic prospects of CAR T cell immunotherapies

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 3575

Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA

Dr Velamehr speaks with ecancer at AACR 2018 about developing a cell bank for quicker production of CAR-T cell therapy.

Dr Velamehr outlines the utility of clinical experience working with induced pluripotent stem cells (IPSCs), the broader economic viability of CAR T cell therapy, and scaling production to improve the availability and viability of off-the-shelf approaches to immunotherapy.

Watch his presentation at the conference here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation